SanBio Co Ltd (TSE:4592)
円 1150 375 (48.39%) Market Cap: 78.92 Bil Enterprise Value: 75.56 Bil PE Ratio: 0 PB Ratio: 32.88 GF Score: 35/100

Q2 2019 SanBio Co Ltd Earnings Call Transcript

Sep 19, 2019 / 06:30AM GMT
Release Date Price: 円3540 (-0.42%)
Keita Mori
SanBio Company Limited - Co-Founder, President, Executive Officer & Representative Director

Hello again. This is Keita Mori from SanBio, and thanks for this opportunity to provide the update 2x a year basis.

So today, I will go over these financial results of the second quarter of this fiscal year. Before we -- before I start talking the updates, first of all, I'd like to provide you with the latest, latest exciting updates that we just announced earlier today. This is -- we have recently obtained RMAT designation. This is Regenerative Medicine Advanced Therapy designation from the Food and Drug Administration in the United States. This is similar to a Breakthrough Therapy designation, which is -- which has all the benefits and acceleration potential for drug approval, and this RMAT is even better than Breakthrough Therapy designation.

So this year, as I look back earlier this year, we've got the Sakigake Designation from PMDA in Japan. Just lately, we got the RMAT designation from the FDA. This is a reflection of the, I think, a strong interest and endorsement from

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot